Skyrizi 600 mg concentrate for solution for infusion

Investigating the safety, feasibility, and optimal dose of risankizumab-800CW for visualizing drug targeting in Inflammatory Bowel Disease

Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease